Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.32K % +145%
Debt-to-equity 4.83 % -60%
Return On Equity -9.22 % +48.4%
Return On Assets -8.8 % +44.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.1M shares +14.4%
Common Stock, Shares, Outstanding 59.1M shares +27.7%
Entity Public Float 1.3B USD +365%
Common Stock, Value, Issued 59K USD +28.3%
Weighted Average Number of Shares Outstanding, Basic 53.8M shares +22.1%
Weighted Average Number of Shares Outstanding, Diluted 53.8M shares +22.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 68.4M USD +24.5%
General and Administrative Expense 41M USD +57%
Operating Income (Loss) -98.8M USD -35.4%
Nonoperating Income (Expense) 29.9M USD +103%
Net Income (Loss) Attributable to Parent -69M USD -18.4%
Earnings Per Share, Basic -1.28 USD/shares +3.03%
Earnings Per Share, Diluted -1.28 USD/shares +3.03%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 431M USD +2142%
Accounts Receivable, after Allowance for Credit Loss, Current 7.5M USD
Assets, Current 1.03B USD +196%
Property, Plant and Equipment, Net 4.86M USD -30.5%
Operating Lease, Right-of-Use Asset 19.3M USD -7.45%
Other Assets, Noncurrent 2.88M USD +14.9%
Assets 1.06B USD +179%
Accounts Payable, Current 4.03M USD +66.1%
Employee-related Liabilities, Current 4.57M USD +38.2%
Accrued Liabilities, Current 11.7M USD +58.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 17.5M USD +34%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 21.3M USD -7.6%
Liabilities 38.7M USD +7.42%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.16M USD +225%
Retained Earnings (Accumulated Deficit) -238M USD -40.9%
Stockholders' Equity Attributable to Parent 1.02B USD +197%
Liabilities and Equity 1.06B USD +179%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.8M USD -6.66%
Net Cash Provided by (Used in) Financing Activities 322M USD +20291%
Net Cash Provided by (Used in) Investing Activities -114M USD -1201%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 59.1M shares +27.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 66.7M USD +48.4%
Deferred Tax Assets, Gross 73.4M USD +39.5%
Operating Lease, Liability 23M USD -6.18%
Depreciation 532K USD +17.4%
Payments to Acquire Property, Plant, and Equipment 197K USD -30.9%
Lessee, Operating Lease, Liability, to be Paid 31.5M USD -9.74%
Property, Plant and Equipment, Gross 9.82M USD -1.02%
Operating Lease, Liability, Current 1.75M USD +15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.61M USD +3.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.51M USD +3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.51M USD -18.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 25.7M USD +37%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.03M USD +68.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.83M USD +2.99%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.66M USD -12.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%